Studies were carried out to determine the prevalence of malaria parasite infection among infants and children (0-12yrs) in Ota, Southwestern Nigeria between April and December 2008. The two hospitals used were Ota General Hospital and Covenant University Health Centre, Canaanland, Ota. Thick and thin films were made and stained using standard parasitological procedures. Structured Questionnaires were distributed to ascertain the age, sex, drugs or insecticides used and state of health of the subjects before recruiting them into the study. Overall, 215 (80.5%) of the 267 children investigated were found to have malaria infection. Age group (0-5 years) had the highest frequency rate of 84.7% with mean parasite density of 900 and the difference between the age groups was statistically significant (p<0.05). Children of illiterates from suburb villages had the highest mean parasite density of 850 with 78.1% prevalence rate. 20% of the children were given local herbs and 22% used orthodox medicine as prophylaxis. Only 18% used insecticide treated mosquito nets while 24% of the parents spray insecticides to prevent mosquito bites. There is therefore need for more awareness on effective use of drugs and Insecticide Treated bed nets in malaria hyperendemic regions.

No abstract

A non-cancer inhalation chronic toxicity assessment for diethylamine (DEA, CAS number 109-89-7) was conducted by the Texas Commission on Environmental Quality. A chronic Reference Value (ReV) was determined based on a high-quality study conducted in mice and rats by the National Toxicology Program. Chronic inhalation ReVs are health-based exposure concentrations used in assessing health risks of long-term (i.e. lifetime) chemical exposure. DEA is used industrially as an organic intermediate to produce corrosion inhibitors, and is widely used in rubber, pharmaceuticals, resins, pesticides, insect repellants, dye processing and as a polymerization inhibitor. Although systemic effects have been noted at higher concentrations, DEA acts primarily as a respiratory irritant with effects occurring in the upper respiratory tract. Rats were exposed to 0, 31, 62.5 and 125 ppm DEA and mice to 0, 16, 31 and 62.5 ppm DEA for 6 h/day, 5 days/week for 105 weeks. Mice were slightly more sensitive than rats. The critical effect identified in mice was hyperostosis in the turbinates although DEA caused a number of other non-neoplatic lesions. Dose–response data were suitable to benchmark concentration (BMC) modeling. The human equivalent point of departure (PODHEC) was calculated from the 95% lower limit of the BMC(10) using default duration and animal-to-human dosimetric adjustments. Total uncertainty factors of 90 were applied to the PODHEC to account for variation in sensitivity within the human population, toxicodynamic differences between mice and humans, and database uncertainty. The chronic ReV for DEA is 11 ppb (33 µg/m3).

No abstract